File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study

TitleSafety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study
Authors
Keywordsepidemiology
gastroenterology
gastrointestinal tumours
preventive medicine
primary care
Issue Date2022
Citation
BMJ Open, 2022, v. 12, n. 2, article no. e050510 How to Cite?
AbstractObjectiveTo assess the association between low-dose aspirin and the incidence of colorectal cancer (CRC), gastric cancer (GC), oesophageal cancer (EC) and gastrointestinal bleeding (GIB) in adults without established atherosclerotic cardiovascular disease.DesignCohort study with propensity score matching of new-users of aspirin to non-users.SettingClinical Data Analysis and Reporting System database, Hong Kong.ParticipantsAdults ≥40 years with a prescription start date of either low-dose aspirin (75–300 mg/daily) or paracetamol (non-aspirin users) between 1 January 2004 to 31 December 2008 without a history of atherosclerotic cardiovascular disease.Main outcome measuresThe primary outcome was the first diagnosis of gastrointestinal cancer (either CRC, GC or EC) and the secondary outcome was GIB. Individuals were followed from index date of prescription until the earliest occurrence of an outcome of interest, an incident diagnosis of any type of cancer besides the outcome, death or until 31 December 2017. A competing risk survival analysis was used to estimate HRs and 95% CIs with death as the competing risk.ResultsAfter matching, 49 679 aspirin and non-aspirin users were included. The median (IQR) follow-up was 10.0 (6.4) years. HRs for low-dose aspirin compared with non-aspirin users were 0.83 for CRC (95% CI, 0.76 to 0.91), 0.77 for GC (95% CI, 0.65 to 0.92) and 0.88 for EC (95% CI, 0.67 to 1.16). Patients prescribed low-dose aspirin had an increased risk of GIB (HR 1.15, 95% CI, 1.11 to 1.20), except for patients prescribed proton pump inhibitors or histamine H2-receptor antagonists (HR 1.03, 95% CI, 0.96 to 1.10).ConclusionIn this cohort study of Chinese adults, patients prescribed low-dose aspirin had reduced risks of CRC and GC and an increased risk of GIB. Among the subgroup of patients prescribed gastroprotective agents at baseline, however, the association with GIB was attenuated.
Persistent Identifierhttp://hdl.handle.net/10722/341344
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShami, Jessica J.P.-
dc.contributor.authorZhao, Jiaxi-
dc.contributor.authorPathadka, Swathi-
dc.contributor.authorWan, Eric Yuk Fai-
dc.contributor.authorBlais, Joseph Edgar-
dc.contributor.authorVora, Pareen-
dc.contributor.authorSoriano-Gabarró, Montse-
dc.contributor.authorCheung, Ka Shing-
dc.contributor.authorLeung, W. K.-
dc.contributor.authorWong, Ian C.K.-
dc.contributor.authorChan, Esther W.-
dc.date.accessioned2024-03-13T08:42:04Z-
dc.date.available2024-03-13T08:42:04Z-
dc.date.issued2022-
dc.identifier.citationBMJ Open, 2022, v. 12, n. 2, article no. e050510-
dc.identifier.urihttp://hdl.handle.net/10722/341344-
dc.description.abstractObjectiveTo assess the association between low-dose aspirin and the incidence of colorectal cancer (CRC), gastric cancer (GC), oesophageal cancer (EC) and gastrointestinal bleeding (GIB) in adults without established atherosclerotic cardiovascular disease.DesignCohort study with propensity score matching of new-users of aspirin to non-users.SettingClinical Data Analysis and Reporting System database, Hong Kong.ParticipantsAdults ≥40 years with a prescription start date of either low-dose aspirin (75–300 mg/daily) or paracetamol (non-aspirin users) between 1 January 2004 to 31 December 2008 without a history of atherosclerotic cardiovascular disease.Main outcome measuresThe primary outcome was the first diagnosis of gastrointestinal cancer (either CRC, GC or EC) and the secondary outcome was GIB. Individuals were followed from index date of prescription until the earliest occurrence of an outcome of interest, an incident diagnosis of any type of cancer besides the outcome, death or until 31 December 2017. A competing risk survival analysis was used to estimate HRs and 95% CIs with death as the competing risk.ResultsAfter matching, 49 679 aspirin and non-aspirin users were included. The median (IQR) follow-up was 10.0 (6.4) years. HRs for low-dose aspirin compared with non-aspirin users were 0.83 for CRC (95% CI, 0.76 to 0.91), 0.77 for GC (95% CI, 0.65 to 0.92) and 0.88 for EC (95% CI, 0.67 to 1.16). Patients prescribed low-dose aspirin had an increased risk of GIB (HR 1.15, 95% CI, 1.11 to 1.20), except for patients prescribed proton pump inhibitors or histamine H2-receptor antagonists (HR 1.03, 95% CI, 0.96 to 1.10).ConclusionIn this cohort study of Chinese adults, patients prescribed low-dose aspirin had reduced risks of CRC and GC and an increased risk of GIB. Among the subgroup of patients prescribed gastroprotective agents at baseline, however, the association with GIB was attenuated.-
dc.languageeng-
dc.relation.ispartofBMJ Open-
dc.subjectepidemiology-
dc.subjectgastroenterology-
dc.subjectgastrointestinal tumours-
dc.subjectpreventive medicine-
dc.subjectprimary care-
dc.titleSafety and effectiveness of low-dose aspirin for the prevention of gastrointestinal cancer in adults without atherosclerotic cardiovascular disease: a population-based cohort study-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1136/bmjopen-2021-050510-
dc.identifier.pmid35121597-
dc.identifier.scopuseid_2-s2.0-85124173651-
dc.identifier.volume12-
dc.identifier.issue2-
dc.identifier.spagearticle no. e050510-
dc.identifier.epagearticle no. e050510-
dc.identifier.eissn2044-6055-
dc.identifier.isiWOS:000754022100009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats